麻豆女优

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • 麻豆女优 Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Community Health Workers
  • Rural Health Payout
  • Measles Outbreaks
  • Doctors’ Liability Premiums
  • Florida鈥檚 KidCare

TRENDING TOPICS:

  • Community Health Workers
  • Rural Health Payout
  • Measles Outbreaks
  • Doctors' Liability Premiums
  • Florida鈥檚 KidCare

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Apr 20 2016

Full Issue

'Quality And Safety' Issues Halt Work At NIH Labs For Internal Inquiry

Lab conditions and the risk of contamination were determined to not be suitable to produce clinical-study drugs at two facilities. No evidence of patient harm has been found.

The National Institutes of Health shut down production of clinical-study drugs at two laboratories after an internal inquiry found them 鈥渘ot in compliance with quality and safety standards.鈥 One lab of the National Cancer Institute, and another of the National Institute of Mental Health, weren鈥檛 suitable to produce the sterile or infused drugs that have been used in clinical studies, the inquiry found. However, NIH officials said they are working rapidly and hope to have the laboratories up and running again soon. (Burton, 4/19)

"There is no evidence that any patients have been harmed, but a rigorous clinical review will be undertaken," the NIH said in a statement provided to NPR Tuesday. "NIH will not enroll new patients in affected trials until the issues are resolved." (Greenfieldboyce, 4/19)

The National Institutes of Health has suspended operations at two of its facilities involved in clinical research trials after a probe last year identified serious contamination problems. (Scott, 4/19)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 麻豆女优